Expected survival of cancer patients and myeloma undergoing bisphosphonates or denosumab. Potential impact on diagnosis and management of Osteonecrosis of Jaws (ONJ)

Vittorio Fusco¹, MARCO CABRAS², Alessio Gambino², Massimo DI MAIO³, Roberto Freilone³, Marco Tampellini⁴, Incoronata Romaniello⁵, Maria Rosa Alvaro⁶, Gianmauro Numico⁷, Maura Rossi¹, Cinzia Ortega, Marcello Tucci⁸, Davide Ottaviani⁹, LUCIO BUFFONI⁹, Giorgio Scagliotti², Giorgio Vellani¹⁰, Paola Varese¹¹, Mario Franchini¹², claudia galassi¹³

¹ Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo
² University of Turin
³ A.O.U. Città della Salute e della Scienza di Torino
⁴ Azienda Sanitaria Locale Torino 3
⁵ ASL Novara
⁶ Azienda USL Valle d’Aosta
⁷ Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo
⁸ Azienda Sanitaria Locale Asti
⁹ Humanitas Gradenigo
¹⁰ A.S.L. TO4
¹¹ ASL AL
¹² Azienda Sanitaria Locale Verbano-Cusio-Ossola
¹³ Centro di Riferimento per l’Epidemiologia e la Prevenzione Oncologica in Piemonte

Funding: The author(s) received no specific funding for this work.

Potential competing interests: The author(s) declared that no potential competing interests exist.

Abstract

Survival of cancer and myeloma patients after diagnosis of bone lesions is largely variable. Appropriate medical therapy together with antiresorptive treatment (bisphosphonates or denosumab) can obtain prolonged survival with adequate
quality of life. Osteonecrosis of Jaws (ONJ) is not rare in patients with bone metastatic cancer and myeloma patients, occurring mostly after prolonged antiresorptive treatment. Expected survival can influence the choice of antiresorptive treatment, the perception of ONJ risk, and even the ONJ management. We reviewed survival data after start of antiresorptive treatment of 509 ONJ patients registered in a cancer network database (Rete Oncologica Piemonte-Valle d’Aosta, North-Western Italy).

Main characteristics: 196 males, 313 females; median age: 68 (39-89) years. Underlying disease: breast cancer: 42.9%; myeloma: 25.3%; prostate cancer: 17.2%; lung cancer: 6.7%; renal cancer: 2.5%; other cancer types: 4.3%. Main antiresorptive treatment: zoledronic acid: 79.4%; denosumab: 5.3%; other drugs/sequences: 15.3%.

Actuarial median survival (range) after the start of antiresorptive treatment was 66.0 (95% CI 57-77) months for breast cancer patients, 77.3 (95% CI 61.9-86.8) months for myeloma patients, 47.3. (95% CI 37.8-51.9) months for prostate cancer patients, 29.4 (95% CI 20.4-40.1) months for lung cancer patients, 39.4 (95% CI 20-107.3) months for renal cancer patients, 82.4 (95% CI 51.9-150.9) months for other cancer patients.

Two-, three- and four-year actuarial survival rates were respectively 91.7%, 80.2%, 67.4% for breast cancer patients, 91.4%, 83.7%, 68.9% for myeloma patients, 78.4%, 61.2%, 41.9% for prostate cancer patients; 55.8%, 32.3%, 23.5% for lung cancer patients; 61.5%, 53.8%, 46.1% for renal cancer patients; 81.8%, 77.3%, 68.1% for others cancer types.

Our data support careful evaluation of short and long-term actuarial ONJ risk (versus short-term absolute risk) in the choice of antiresorptive treatment duration for bone metastatic cancer and myeloma patients. Furthermore, exclusion of jawbone surgery due to expected short survival in most of ONJ patients seems not warranted.

**Background:** Expected survival of patients with bone metastases of solid tumors (breast, prostate, lung, renal cancer, etc) [1][2][3] and of myeloma patients [4][5] is largely variable in “real life” (outside clinical trials), with early deaths and patients surviving many years. Such a variability was broadened by recent introduction or improvement of several medical therapies (endocrine agents, chemotherapy, biological agents, immunotherapy, etc) in almost each of the aforesaid cancer populations. Patients with bone metastases and myeloma usually receive antiresorptive treatment (bisphosphonates or denosumab) together with main medical therapies, with the aim to reduce the risk of SRE (Skeletal Related Events, such as bone fractures, cord compression, need of radiotherapy or surgery) and to delay SRE onset. However, antiresorptive agents are associated with adverse events, including Osteonecrosis of Jaw (ONJ) that can occur in 1-15 % of cancer and myeloma patients undergoing antiresorptive therapy. The ONJ risk increases with antiresorptive treatment duration and with the time of observation (survival). Little data have been published so far about length of survival of ONJ patients, as well as survival of patients receiving antiresorptive treatments in “real life”. This kind of survival data might be useful in choosing both the most appropriate antiresorptive therapy (drug of choice; initial planned duration; monthly vs trimestral administrations; eventual discontinuation) as well as the most effective ONJ treatment: “conservative” versus surgical treatment, the latter being restricted according to some recommendations [6][7] but encouraged by several other authors and groups [8][9][10][11]. Herein we report the survival of ONJ cancer and myeloma patients, after the start of antiresorptive treatment, from a large regional case series. [12][13]

**Materials and Methods:** Along 16-years (Jan 1st, 2003-31th Dec, 2018), retrospective collection of patient characteristics,
clinic and prognostic data was investigated. Medical oncology, haematology, and oral care Units of North-Western Italy (Rete Oncologica di Piemonte e Valle d’Aosta) were consulted to acquire data of ONJ patients. Acquisition of the following data was pursued: sex and age distribution, underlying cancer disease, type of drug regimen administered—zoledronate, denosumab, others—and date of death of deceased patients. Kaplan-Meier curves were deployed to obtain the actuarial median of survival after the beginning of antiresorptive treatment (bisphosphonates or denosumab), expressed in months, as well as the actuarial survival rate at two, three and four years.

**Results** Data from 509 patients (196 M, 313 F) were acquired. Median age was of 68 (32-90) years, with 115 (22.6%) under 60 years old, 170 (33.4%) of 60-70 years old, 224 (44%) over 70 years old.

Underlying diseases were: breast cancer (218/509, 43%), multiple myeloma (129/509, 25.3%), prostate (93/509, 18.3%) lung cancer (34/509, 6.7%), renal cell cancer (13/509, 2.5%), other type of cancer (22/509, 4.2%).

Sex distribution for each cancer was as follows: breast cancer 5 M, 213 F; prostate cancer: 93 M; multiple myeloma: 55 M, 74 F; lung cancer: 17 M, 17 F; renal cancer 11 M 2 F; other cancers: 15 M, 7 F.

Median age (+ DS) at ONJ diagnosis for each cancer was as follows: breast cancer: 67 ± 9.1 (range 39-89) years; prostate cancer: 71 ± 5.5 (age range 55-86) years; myeloma: 72 ± 7.4 (range 47-89) years; lung cancers: 67 ± 7.2 (range: 49-80) years; renal cancers: 59 ± 6.4 (age range 46-73) years; others: 66 ± 8.5 (range 40-83) years.

Main antiresorptive treatment was as follows: zoledronic acid: 79.4%; denosumab: 5.3%; other drugs/sequences: 15.3%.

Observed actuarial median survival after start of treatment was as follows:

- breast cancer 66 (95% CI: 57-77) months (Fig.1);
- prostate cancer 47.3 (95% CI: 37.8-51.9) months (Fig.2);
- multiple myeloma 77.3 (95% CI: 61.9-86.8) months (Fig.3);
- lung cancer 29.4 (95% CI: 20.4-40.1) months;
- renal cancer 39.4 (95% CI: 20-107.3) months;
- other cancers 82.4 (95% CI: 51.9-150.9) months.

From the actuarial survival curves the following survival rates emerged at 2, 3, 4 years, respectively:

- breast cancer : 91.7%, 80.2%, 67.4%;
- myeloma: 91.4%, 83.7%, 68.9%;
- prostate cancer : 78.4%, 61.2%, 41.9%;
- lung cancer : 55.8%, 32.3%, 23.5%;
- renal cancer : 61.5%, 53.8%, 46.1%;
- other cancers: 81.8%, 77.3%, 68.1%.

![Fig. 1 Breast cancer patients: actuarial (Kaplan-Meier) survival curve](https://doi.org/10.32388/MQ2IYG)
Conclusions: In ONJ patients, expected survival after the start of antiresorptive treatment is medically long some years. The comparison of this survival with that of “real life” patients undergoing antiresorptive treatment and not developing ONJ (overall, and long surviving) might be of value: a) to predict the ONJ risk among long surviving patients; b) to establish the real ONJ risk in patients surviving more than one or two years (and to choose the best antiresorptive treatment duration); c) to evaluate the chance of surgical treatment of ONJ disease (often denied on the base of a supposed expected short survival).

References


